Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

• Status: Terminated
• Trial end date: 2017-06-29
• Target enrollment: 0
• Participant gender: All

Summary

We assess the effectiveness of percutaneous ethanol ablation for the treatment of thyroid cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Ethanol

Criteria

Inclusion Criteria:

• Age 18 years and older

• Diagnosis: single, cytology-proven papillary thyroid carcinoma measuring 1 cm or less in diameter (microcarcinoma, T1a), without visible extrathyroidal extension, and with negative central and lateral neck lymph nodes by ultrasound

Exclusion Criteria:

• Patient refusal to participate

• History of prior thyroid or parathyroid surgery

• Previous recurrent laryngeal nerve injury

• Inability to make decisions or comply with follow up

• Co-existing indication for thyroidectomy

• Aggressive cytological or molecular features

• Multifocal papillary thyroid carcinoma

• Pregnant or breast-feeding

• Anatomically unfavorable location of the tumor (proximity to recurrent laryngeal nerve or trachea)

• Documented or suspected distant metastasis

• History of radiation to neck or face

• Family history of thyroid cancer